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Strengthening National Preparedness
for Smallpox: An Update
Concern that smallpox virus may be used as
a biological weapon of mass destruction has
prompted calls for production of additional
vaccine and new research into variola virus
diagnostics and clinical interventions. Only 15.4
million doses of smallpox vaccine, produced
approximately 20 years ago, exist in the United
States (1). While virtually all lots remain
potent, additional vaccine would clearly be
needed in a national emergency involving
smallpox virus. Global eradication of natural
smallpox disease was declared in 1980; with
eradication, most research activities involving
the virus ended. Although the complete ge-
nomic sequence of selected isolates of variola
virus is known (2), the diagnosis and treatment
of smallpox infection have not changed in the
past two decades. Recognizing the need for
advancement in these areas before variola virus
stocks are destroyed, the World Health Organi-
zation (WHO) passed a resolution (WHA 52.10)
in 1999 extending the date of destruction of all
remaining variola virus stocks until the end of
2002. The midpoint of this period is an appro-
priate time to review progress made in vaccine
production and variola virus research and to
outline the next steps.
Vaccine Production
On September 20, 2000, the Centers for
Disease Control and Prevention (CDC) entered
into an agreement with OraVax (Cambridge,
MA) to produce a new smallpox vaccine. Like
the vaccine used to eradicate smallpox, the new
vaccine will contain live vaccinia virus; how-
ever, it will be produced in cell cultures by
modern vaccine production techniques. OraVax
will coordinate full clinical testing of the vac-
cine and submit a licensing application to the
U.S. Food and Drug Administration (FDA) for
the prevention of smallpox in adults and chil-
dren. Forty million doses of the new vaccine
will be produced initially, with anticipated
delivery of the first full-scale production lots in
2004. The agreement calls for sustained annual
production through 2020 to replace outdated
vaccine and allows for increased production
should an emergency arise. The vaccine will be
administered with bifurcated needles (also
produced by OraVax), which create a localized
vaccine “pock” and confer protective immunity.
The vaccine will be held in reserve as part of
the national stockpile and be released only in
the event of a confirmed case of smallpox or
when vaccination against vaccinia virus is
warranted. The agreement allows OraVax to
produce additional vaccine for other markets,
including international buyers.
Variola Virus Research
A research plan, implemented at CDC by
scientists from both the Department of Defense
and CDC and including extensive collaborations
with scientists from the National Institutes of
Health and other organizations, is being under-
taken with WHO concurrence. All work with
live variola virus is done under biosafety level 4
containment conditions at CDC. Smallpox virus
is officially retained at only two facilities in the
world: at CDC in the United States and the
State Research Center of Virology and Biotech-
nology in Novosibirsk, Russia. Research teams
from both institutions are coordinating activi-
ties to avoid duplication and gain the maximum
amount of information possible before final
destruction of the virus.
Strain Evaluation
Of 461 isolates in the smallpox virus collec-
tion at CDC, 49 were selected for further
characterization. These isolates, which included
both variola major and variola minor, were
selected to represent the greatest diversity in
date of collection and geographic region. Of the
49 isolates tested for viability, 45 were success-
fully recovered, and seed stocks were prepared
for subsequent studies. This group of 45 repre-
sented isolates from as early as 1939 and as
late as the 1970s; all major geographic regions
were represented. Study of these isolates is
based on three research themes: application of
modern serologic and genomic methods in the
diagnosis of variola virus disease; determina-
tion of candidate antiviral drug activity against
this virus; and investigation of the pathogenesis
of smallpox infection, especially through the
development of a nonhuman primate model to
replicate human smallpox infection. The re-
search team carefully outlined all experimental
work to be undertaken with variola virus,
incorporating suggestions from a peer group of
highly qualified external experts from academia
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conducted from January to July 2000 in the
CDC maximum containment laboratory.
Serologic Assays
Because enzyme immunoassay technology
was still in its infancy when smallpox was
eradicated, during the first series of experi-
ments, polyclonal and monoclonal antibodies
had to be produced for developing enzyme-
linked immunosorbent assays to measure
variola virus-specific immunoglobulin (Ig) M,
IgG, and antigen. These reagents are now being
evaluated by prototype assays with inactivated
viral antigens. This work will continue for the
foreseeable future.
Nucleic Acid-Based Diagnostics
Viral DNA was extracted from all 45 suc-
cessfully recovered isolates, was purified and
inactivated, and is now being examined by
restriction fragment-length polymorphism
developed by an extended polymerase chain
reaction assay that amplifies viral genome into
20 overlapping products of approximately 10
kilobases each. These products cover virtually
the entire length of the viral genome and
include sequences in essential genes and genes
likely needed for pathogenesis. Preliminary
results indicate that the data thus generated
offer a good low-resolution overview of genetic
diversity of variola viruses and are being used
to differentiate strains, infer phylogeny, and
identify as many as 10 additional variola
isolates for complete genome sequencing. Two
isolates, Somalia 77 and Congo 70, were specifi-
cally suggested by WHO for sequencing, and
this work has begun. A dedicated sequence and
bioinformatics facility being developed at CDC
will be used to undertake this effort and to
begin constructing a genomic signature data-
base, not only for smallpox but also, over time,
for other pathogens with bioterrorism potential.
Antiviral Drugs
Two hundred seventy-four antiviral drug
compounds were screened for activity and
therapeutic indices against variola, monkeypox,
cowpox, camelpox, and vaccinia viruses by two
cell culture assays. Many of these compounds
were provided for testing under collaborative
arrangements facilitated by an orthopox antivi-
ral research initiative of the National Institute
of Allergy and Infectious Diseases. Previous
studies identified a nucleoside phosphonate
DNA polymerase inhibitor, cidofovir (Vistide),
as being active against poxviruses, including
variola. In the current trial, cidofovir and its
prodrug (cyclic HPMPC) were evaluated against
31 strains of variola, which were selected to
cover a wide geographic area and time span. No
substantial differences in inhibition among
strains were observed, which suggests that
cidofovir-resistant strains are unlikely. The in
vitro inhibition was further characterized in
multiple cell lines to meet FDA requirements.
However, another class of antiviral drugs, the
S-adenosylhomocysteine hydrolase inhibitors,
showed considerable variation in the 50%
inhibitory dose between variola isolates; this
effect should be investigated further.
Two approaches to the development of an
oral prodrug of cidofovir yielded compounds
with improved antiviral activity. In addition,
the current series of experiments identified 27
other compounds, including completely new
classes of drugs, that appear to be active
against variola and other orthopoxviruses. In
fact, 10 compounds had therapeutic indices
greater than 200, while cidofovir had indices
greater than 10; 3 compounds had therapeutic
indices greater than 1,500. When work resumes
in early 2001 with live variola virus, we will
continue to evaluate these and additional
compounds for activity, including analogs
designed for oral administration. The most
promising compounds emerging from this in
vitro testing will be evaluated in animal mod-
els, e.g., cowpox and vaccinia in mice and
eventually monkeypox virus challenge in
nonhuman primates. All promising compounds
will be tested against a battery of surrogate
orthopox viruses to guide evaluation of new
antiviral compounds after variola virus is no
longer available.
Animal Models
A major goal of the current research is to
define an animal model that faithfully repli-
cates human smallpox. Such a model would be
extremely valuable in evaluating candidate
antiviral drugs and novel diagnostic assays and
in defining the pathogenesis of smallpox.
Consequently, two groups of four cynomolgus
macaques were exposed to two variola virus
strains at a high dose (>108 PFU) by the aerosol
route. Clear evidence of infection was found; the157 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
Research Update
animals had transient fevers, perturbations in
cytokine titers in serum, and mild exanthemous
lesions. A few of the monkeys showed signs of
bronchopneumonia, but none died or had
disease similar to the classic smallpox seen in
humans. Another series of experiments will be
undertaken with different variola isolates to
confirm these preliminary observations and
generate additional clinical material to validate
the diagnostic assays under development.
The results of the research now under way,
coupled with the promise of renewed production
of smallpox vaccine, will better prepare the
United States—and indeed the entire world—
for the possibility that smallpox virus might be
used as a terrorist weapon of mass destruction.
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